February 20, 2025: Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations - Microbiome Times - MaaT Pharma

To see the interview, click here!

Previous PostMarch 11, 2025: MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013
Next PostFebruary 10, 2025: MaaT Pharma : Pioneering microbiome-driven therapy as new pillar in oncology - Fierce Pharma

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club